AbbVie

AbbVie EBIT Margin

The EBIT Margin (Operating Margin) of AbbVie (ABBV) as of Nov 18, 2026 is 32.85 %. In the previous year, EBIT Margin (Operating Margin) was 16.22 % — a change of 102.54% (higher).

EBIT Margin

32.85 %

YoY

102.54%

Last updated:

EBIT Margin (Operating Margin) of AbbVie is 2025 32.85 % . EBIT Margin (Operating Margin) of AbbVie was 2024 16.22 % . It decreases by 102.54% higher compared to the previous year.

For AbbVie, the operating (EBIT) margin of 32.8% is broadly stable versus 31.9% a few years ago.

The AbbVie EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
19.49 USD
Jan 1, 2019
39.03 USD
Jan 1, 2020
24.81 USD
Jan 1, 2021
31.89 USD
Jan 1, 2022
31.21 USD
Jan 1, 2023
23.49 USD
Jan 1, 2024
16.22 USD
Jan 1, 2025
32.85 USD
The AbbVie EBIT Margin history
YEAREBIT MarginYoY
32.85 %+102.54%
16.22 %-30.94%
23.49 %-24.74%
31.21 %-2.16%
31.89 %+28.57%
24.81 %-36.44%
39.03 %+100.26%
19.49 %-42.39%
33.83 %-7.14%
36.43 %+10.49%
32.97 %+92.94%
17.09 %+5,569.24%
0.30 %-4.75%
0.32 %+52.51%
0.21 %-31.20%
0.30 %-13.06%
0.35 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AbbVie Stock analysis

What does AbbVie do? Abbvie Inc. is a global, research-oriented company specializing in the field of biotechnology and pharmaceuticals. It was founded in 2013 as a spin-off from Abbott Laboratories. Abbvie's headquarters are in North Chicago, Illinois, and it employs over 47,000 people in more than 75 countries worldwide. The company focuses on researching, developing, and marketing high-quality therapies for the treatment of serious and life-threatening diseases. Abbvie has several business divisions, including immunology, oncology, neurology, and virology, and is known for its investments in research and development. Its key products include adalimumab (sold under the brand name Humira) for autoimmune diseases and Imbruvica for chronic lymphocytic leukemia. Abbvie is recognized as a leading company in the biotechnology and pharmaceutical industry due to its focus on innovative therapies and medicines. AbbVie is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AbbVie stock

EBIT Margin (Operating Margin) of AbbVie is 32.85 % in 2025.

EBIT Margin (Operating Margin) of AbbVie changed from 16.22 % to 32.85 %, representing a 102.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) AbbVie since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s AbbVie with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — AbbVie

All Key Metrics — AbbVie